At Santhera, we are passionate about providing treatment options for patients with rare diseases, specifically in the area of neuromuscular conditions – diseases that have a severe impact on the lives of affected children and adults.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company committed to developing and commercializing innovative medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs.

Find the latest Santhera Pharmaceuticals Holding AG (SANN.SW) stock quote, history, news and other vital information to help you with your stock trading and investing.

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need.

2022年1月4日 · Santhera的主要产品管线包括目前正在开展治疗DMD关键临床试验的Vamorolone，和处于临床阶段的治疗囊性纤维化及其他中性粒细胞肺病的Lonodelestat，以及一款治疗先天性肌营养不良的探索性基因疗法。

3 天之前 · Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and …

2025年3月24日 · Santhera has out-licensed rights to AGAMREE for North America to Catalyst Pharmaceuticals and for China and certain countries in Southeast Asia to Sperogenix Therapeutics.

2023年10月13日 · 2023年4月25日， 中国国家药品监督管理局药品审评中心（CDE） 受理品种信息显示， Santhera Pharmaceuticals 和 曙方医药（Sperogenix） 联合提交了治疗 杜氏肌营养不良（DMD） 新药vamorolone口服混悬液的临床试验申请。

2025年2月13日 · Santhera has reached an agreement with health insurance funds in Germany on reimbursement of its Agamree treatment for Duchenne muscular dystrophy (DMD) that should support broad use of the...

3 天之前 · Get Santhera Pharmaceuticals Holding AG (SANN.S) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments